Related references
Note: Only part of the references are listed.An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort
Penny Watson et al.
RHEUMATOLOGY (2015)
Annual direct medical cost of active systemic lupus erythematosus in five European countries
Andrea Doria et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus
Ellen M. Ginzler et al.
JOURNAL OF RHEUMATOLOGY (2014)
Systemic lupus erythematosus one disease or many?
N. Agmon-Levin et al.
AUTOIMMUNITY REVIEWS (2012)
Mortality Profile Related to Systemic Lupus Erythematosus: A Multiple Cause-of-death Analysis
Deborah C. C. Souza et al.
JOURNAL OF RHEUMATOLOGY (2012)
Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort
Rekha Lopez et al.
RHEUMATOLOGY (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice
M. Mosca et al.
AUTOIMMUNITY REVIEWS (2011)
Treatment for Lupus, First in 50 Years, Offers Modest Benefits, Hope to Patients
Mike Mitka
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
The occurrence of acute myocardial infarction in Italy: a five-year analysis of hospital discharge records
Prisco Piscitelli et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2011)
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies
M. Mosca et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Health Technology Assessment Evaluation of Biomedical Innovative Technologies
Giuseppe Turchetti et al.
IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE (2010)
Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus
J. Nossent et al.
LUPUS (2010)
Employment and work disability in systemic lupus erythematosus: a systematic review
Kim Baker et al.
RHEUMATOLOGY (2009)
Cost of disorders of the brain in Italy
Maura Pugliatti et al.
NEUROLOGICAL SCIENCES (2008)
The NICE cost-effectiveness threshold - What it is and what that means
Christopher McCabe et al.
PHARMACOECONOMICS (2008)
Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual
J. Nossent et al.
LUPUS (2007)
Mortality in systemic lupus erythematosus
S. Bernatsky et al.
ARTHRITIS AND RHEUMATISM (2006)
Revealing the cost of Type II diabetes in Europe
B Jönsson
DIABETOLOGIA (2002)
Total costs and predictors of costs in patients with systemic lupus erythematosus
N Sutcliffe et al.
RHEUMATOLOGY (2001)
Share Paper
